Skip to main content
RemeGen Co., Ltd. logo

RemeGen Co., Ltd. — Investor Relations & Filings

Ticker · 9995 ISIN · CNE1000048G6 LEI · 300300M9HCX4TFAD4I10 HKEX Manufacturing
Open in API
Filings indexed 1,625 across all filing types
Latest filing 2021-02-01 Share Issue/Capital Cha…
Country CN China
Listing HKEX 9995

About RemeGen Co., Ltd.

http://www.remegen.com

RemeGen Co., Ltd. is a biopharmaceutical company dedicated to the discovery, development, production, and commercialization of innovative biological drugs. The company focuses on creating first-in-class and best-in-class therapeutics to address significant unmet clinical needs, particularly in the critical therapeutic areas of autoimmune diseases, oncology, and ophthalmology. RemeGen utilizes proprietary technology platforms capable of discovering, screening, and developing new molecules and efficiently optimizing production processes. Its pipeline includes a series of innovative biologics, such as Telitacicept, and features 8 clinical pipelines, over 40 clinical trials, and more than 600 patent applications, demonstrating a strong commitment to R&D and innovation in biopharmaceuticals.

Recent filings

Filing Released Lang Actions
Monthly Return of Equity Issuer on Movement in Securities for the month ended 31 January 2021
Share Issue/Capital Change Classification · 95% confidence The document is a detailed monthly report on movements in securities, including authorized and issued share capital, share options, warrants, convertibles, and other share-related activities. It is addressed to the Hong Kong Exchanges and Clearing Limited and includes confirmations related to securities issuance and compliance with listing rules. The content focuses on changes in share capital and securities movements rather than financial performance, management changes, or earnings. This type of document aligns with announcements regarding share capital changes and share issues. Therefore, the most appropriate classification is 'Share Issue/Capital Change' (SHA). The document length is substantial and contains detailed data, so it is not merely an announcement of a report but the report itself.
2021-02-01 English
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 December 2020
Capital/Financing Update Classification · 95% confidence The document is titled 'Monthly Return of Equity Issuer on Movements in Securities' for the month ended 31/12/2020 and submitted to the Hong Kong Exchanges and Clearing Limited. It details movements in authorized share capital, issued share capital, share options, warrants, convertibles, and other share-related activities. The content focuses on changes in share capital and securities movements rather than financial performance, earnings, or management commentary. It is a regulatory disclosure about share capital changes and securities movements, typical of a capital or financing update. The document is lengthy (15,000 characters) and contains detailed data on share capital movements, not just an announcement or a brief summary. Therefore, it fits best under the category of Capital/Financing Update (CAP).
2021-01-06 English
Monthly Return of Equity Issuer on Movement in Securities for the month ended 31 December 2020
Regulatory Filings Classification · 95% confidence The document is titled 'Monthly Return of Equity Issuer on Movements in Securities' and details movements in authorized and issued share capital, including share options, warrants, convertibles, and other share-related transactions for the month ended 31/12/2020. It is addressed to the Hong Kong Exchanges and Clearing Limited and includes confirmations related to securities issuance and compliance with listing rules. The content focuses on share capital changes and securities movements rather than financial performance, earnings, or management commentary. It is a regulatory filing reporting monthly share capital movements rather than a full financial report or announcement of a report. Therefore, it fits best under the category of Regulatory Filings (RNS), which covers general regulatory announcements and compliance documents that do not fit other specific categories.
2021-01-04 English
RESULTS OF THE EXTRAORDINARY GENERAL MEETING HELD ON 31 DECEMBER 2020
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is an announcement of the results of an Extraordinary General Meeting (EGM) held on 31 December 2020. It details the voting results on a specific resolution related to the sale and purchase agreement of shares. The document does not contain financial statements or detailed financial analysis but rather the official voting outcome of a shareholder meeting. It explicitly states the resolution was passed by poll and provides voting numbers and percentages. The document length is 4091 characters, which is relatively short and consistent with an announcement rather than a full report. Therefore, this document fits the category of Declaration of Voting Results & Voting Rights Announcements (DVA).
2020-12-31 English
MAJOR TRANSACTION DISPOSAL OF LISTED SECURITIES IN TONGCHENG-ELONG
Capital/Financing Update Classification · 95% confidence The document is a circular from Overseas Chinese Town (Asia) Holdings Limited dated 31 December 2020, concerning a major transaction involving the disposal of listed securities in Tongcheng-Elong. It includes detailed information about the disposals, financial information of the group, definitions, and a letter from the board explaining the transaction, its background, and financial effects. The document is lengthy (15,000 characters) and contains substantive financial data and analysis related to the transaction. It is not a brief announcement or a proxy solicitation but a detailed circular providing comprehensive information about a major transaction. This type of document fits the category of a Capital/Financing Update (CAP), as it relates to updates on company fundraising, financing activities, or capital structure changes through disposal of securities. It is not an Annual Report, Interim Report, or Earnings Release, nor is it a regulatory filing or announcement of a report. Therefore, the appropriate classification is CAP with high confidence.
2020-12-30 English
VOLUNTARY ANNOUNCEMENT - APPROVAL OBTAINED FROM THE FDA FOR A PHASE II CLINICAL TRIAL OF TELITACICEPT FOR THE TREATMENT OF IMMUNOGLOBULIN A NEPHROPATHY IN THE UNITED STATES
Regulatory Filings Classification · 95% confidence The document is a voluntary announcement by RemeGen Co., Ltd. regarding FDA approval to proceed with a Phase II clinical trial for a drug candidate. It is an announcement of a business development event, specifically related to clinical trial approval, and does not contain financial statements, detailed financial analysis, or regulatory filings such as annual or quarterly reports. The document is relatively short (3532 characters) and serves to inform shareholders and investors about a significant business milestone. It does not fit into categories like Annual Report, Interim Report, Earnings Release, or Regulatory Filings. It is not a report publication announcement since it does not mention the release or availability of a report. The content is best classified as a general regulatory announcement about a business development, which fits the Regulatory Filings (RNS) category as a fallback for miscellaneous announcements that do not fit other specific categories.
2020-12-21 English

Browse filings by year

22 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.